{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:22:39Z","timestamp":1757618559855,"version":"3.44.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00228-025-03871-1","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:19:29Z","timestamp":1751422769000},"page":"1329-1332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pretomanid can significantly increase plasma rivaroxaban concentrations\u2014a case report"],"prefix":"10.1007","volume":"81","author":[{"given":"Dali","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teurai","family":"Chikura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"McCrostie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul Ken Leong","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"3871_CR1","doi-asserted-by":"crossref","unstructured":"Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators (2022 ) A 24-Week, all-oral regimen for rifampin-resistant tuberculosis. N Engl J Med 387(25):2331\u20132343","DOI":"10.1056\/NEJMoa2117166"},{"issue":"11","key":"3871_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/psp4.12562","volume":"9","author":"Y Otsuka","year":"2020","unstructured":"Otsuka Y, Choules MP, Bonate PL, Komatsu K (2020) Physiologically-based pharmacokinetic modelling for the prediction of a drug-drug interaction of combined effects on P-glycoprotein and cytochrome P450 3A. CPT Pharmacometrics Syst Pharmacol 9(11):659\u2013669","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"3871_CR3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1124\/dmd.119.086918","volume":"47","author":"EJY Cheong","year":"2019","unstructured":"Cheong EJY, Teo DWX, Chua DXY, Chan ECY (2019) Systematic development and verification of a physiologically based pharmacokinetic model of rivaroxaban. Drug Metab Dispos 47(11):1291\u20131306","journal-title":"Drug Metab Dispos"},{"key":"3871_CR4","unstructured":"US Food and Drug Administration. PRETOMANID label information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/212862s008lbl.pdf. Accessed 13 June 2025."},{"issue":"3","key":"3871_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/FTD.0000000000000744","volume":"42","author":"M Zhang","year":"2020","unstructured":"Zhang M, Moore GA, Chin PKL (2020) Simultaneous determination of dabigatran, rivaroxaban, and apixaban in human plasma by liquid chromatography\/tandem mass spectrometry. Ther Drug Monit 42(3):473\u2013480","journal-title":"Ther Drug Monit"},{"issue":"8","key":"3871_CR6","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1055\/a-1450-8178","volume":"121","author":"J Douxfils","year":"2021","unstructured":"Douxfils J, Adcock DM, Bates SM, Favaloro EJ, Gouin-Thibault I, Guillermo C, Kawai Y, Lindhoff-Last E, Kitchen S, Gosselin RC (2021) Update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 121(8):1008\u20131020","journal-title":"Thromb Haemost"},{"key":"3871_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.thromres.2021.08.010","volume":"206","author":"T Cavaillez","year":"2021","unstructured":"Cavaillez T, Weinmann L, Mouton C, Delassasseigne C, Sesay M, Biais M et al (2021) A retrospective study of indications and consequences of monitoring direct oral anticoagulant plasma concentrations on patient care in a university hospital: The Retro-AOD study. Thromb Res 206:76\u201383","journal-title":"Thromb Res"},{"issue":"1","key":"3871_CR8","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.jcf.2021.10.003","volume":"21","author":"SEM Vonk","year":"2022","unstructured":"Vonk SEM, Terheggen-Lagro SWJ, Mouissie LM, Math\u00f4t RAA, Kemper EM (2022Jan) Amsterdam Mucociliary Clearance Disease (AMCD) research group. No drug-drug interaction between tezacaftor-ivacaftor and clofazimine: A case report. J Cyst Fibros 21(1):e5\u2013e7","journal-title":"J Cyst Fibros"},{"issue":"9","key":"3871_CR9","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1093\/jac\/dku171","volume":"69","author":"RP van Heeswijk","year":"2014","unstructured":"van Heeswijk RP, Dannemann B, Hoetelmans RM (2014) Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother 69(9):2310\u20132318","journal-title":"J Antimicrob Chemother"},{"issue":"13","key":"3871_CR10","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","volume":"42","author":"DJ Stalker","year":"2003","unstructured":"Stalker DJ, Jungbluth GL (2003) Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42(13):1129\u20131140","journal-title":"Clin Pharmacokinet"},{"issue":"32 Suppl 1","key":"3871_CR11","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1086\/319376","volume":"15","author":"H Stass","year":"2001","unstructured":"Stass H, Kubitza D (2001) Profile of moxifloxacin drug interactions. Clin Infect Dis 15(32 Suppl 1):S47-50","journal-title":"Clin Infect Dis"},{"issue":"12","key":"3871_CR12","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.3390\/molecules28124740","volume":"28","author":"Y Chen","year":"2023","unstructured":"Chen Y, Li H, Wang K, Wang Y (2023) Recent advances in synthetic drugs and natural actives interacting with OAT3. Molecules 28(12):4740","journal-title":"Molecules"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03871-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03871-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03871-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:28:51Z","timestamp":1757204931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03871-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3871"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03871-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An ethics committee was not consulted, as this is a case report, and, therapeutic drug monitoring is a routine service provided within our health system.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained in writing from the patient to investigate this drug-drug interaction and to publish any findings in an academic journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no conflicts of interest relevant to this manuscript to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}